普洛藥業(000739.SZ):上海創智擬吸收合併上海裕緣
格隆匯10月19日丨普洛藥業(000739.SZ)公佈,公司為適應經營發展需要,優化公司管理架構,減少管理層級,降低管理成本,公司下屬兩家全資子公司上海普洛創智醫藥科技有限公司(簡稱“上海創智”)與上海裕緣生物醫藥研發有限公司(簡稱“上海裕緣”)進行了吸收合併。上海創智作為合併後存續方將承繼和承接上海裕緣的全部資產、負債、業務、人員及其他一切權利與義務,上海裕緣的法人主體資格將予以註銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.